RBC Capital raised the firm’s price target on Hologic (HOLX) to $89 from $86 and keeps a Sector Perform rating on the shares after its Q4 results and initial FY25 guidance. The firm contends that the outlook is “achievable”, operating margin target of low 30% is “realistic”, and the management’s M&A / buyback focus still “preferable”, the analyst tells investors in a research note. Hologic management has also highlighted its efforts to expand and tap into new international markets, even though these have historically been lower margins than the U.S. business, RBC added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on HOLX:
- Hologic price target raised to $95 from $93 at Raymond James
- Hologic price target lowered to $87 from $90 at Mizuho
- Hologic Reports Robust Q4 2024 Financial Growth
- Closing Bell Movers: Palantir jumps 13% after results
- Hologic sees FY25 EPS $4.25-$4.35, consensus $4.32
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
